RAND Europe has been asked to support the on-going Innovative Medicines and Medical Technologies Review through conducting a study to examine international examples of accelerating the use of drugs, devices and diagnostics.
To understand more about the implications of these long-term funding restrictions, as well as the potential benefits from increasing research spending, the Department of Business, Innovation and Skills has asked RAND Europe to examine — and thus to improve the government's understanding about — the relationship between the level of research spending and research performance, and particularly how changes in research spending relate to changes in performance.
RAND Europe’s growing work in the field of mental health and wellbeing draws on expertise from across a range of disciplines and methodological backgrounds to bring an innovative perspective to our projects. In particular, our well-established reputation in healthcare research is complemented by extensive science policy expertise, particularly in the field of research evaluation.
The International AIDS Vaccine Initiative (IAVI) helps to bridge the gap between scientific and technological potential and the needs of low income populations in low and middle income countries. RAND Europe is evaluating its capacity-building activities — including training, advocacy and broader community engagement activities — in Uganda, Kenya and Rwanda.
RAND Europe is a co-leading organisation for the Governance and Adaptation to Innovative modes of Higher Education provision project, with 12 partners across the EU. This project for the European Commission and the French Ministry for National Education examines innovative modes in teaching and learning and their evolution across Europe.
The Department of Health’s strategy for improving care and creating greater wealth through innovation, known as ‘Innovation, Health and Wealth’ (IHW), has the potential to systematically change the way the NHS operates. RAND Europe is evaluating whether and how IHW actions are working as planned, and contributing to achieving the strategy's overarching aims.
‘Science 2.0’ describes the on-going evolution in the modus operandi of doing research and organising science in Europe. RAND Europe is reviewing the public consultation on this EU project and has developed an interactive website on which participants and interested individuals can comment on the validation process of the public consultation.
The i4i programme supports the development of innovative medical technologies and their translation into clinical practice. RAND Europe is evaluating i4i to identify its impacts and the factors influencing performance.
To support the coordination of mental health research, RAND Europe is mapping the research funding ‘ecosystem’. Researchers are exploring who the major funders are, what kinds of research they support, and how their strategies relate to one another.
To contribute to the Medical Research Council's objective of funding studies that "deliver user/beneficiary views on the contribution of academic research and MRC input," researchers are refining and adapting a survey-based approach known as Best-Worst Scaling (BWS) to analyse the relative valuations of research impact as perceived by the general population and researchers.
Understanding the context and impacts of the complex problems associated with big data, as well as related cultural and governance issues and policy frameworks, is important to businesses, governments, research organisations, citizens and policymakers. RAND Europe connects diverse strands across these areas.
A series of social innovation pilot projects across Europe aim to support the growth of European social finance markets and the development of capacities within social business and young entrepreneurship. RAND Europe and Ecorys are evaluating these pilots and hosting a series of interactive workshops to encourage an exchange of experiences.
To help frame the debate on future EU membership in the context of UK health research, RAND Europe is assessing the benefits and burdens of membership. This research, for the Department of Health, will not only focus on funding, but also look at other aspects such as research environment, network effects, and knowledge spillovers. The project will include a series of scenario-based workshops to explore future impact of EU funding.
CAPREx aims to strengthen Africa’s capacity for sustainable excellence in research through close collaborative work with the region’s most talented individuals. RAND Europe is consulting on the evaluation aspects of the initiative, drawing on established subject and methodological expertise in conducting real-time evaluations of networked research and capacity-building efforts, including in African contexts.
When treating patients for Hepatitis-C, physicians may be influenced by many factors: their prior experience, the health and social care systems more broadly, or clinical, social and behavioural, or demographic factors. To better understand this decision-making process, GlaxoSmithKline commissioned RAND Europe to investigate the comparative influence and importance of specific factors and combinations of factors and their trade-offs.
The performance of health systems is a key determinant of the inclusiveness of economic growth. Exclusionary, poor quality health care worsens impoverishment, while inclusive health care redistributes the benefits of growth toward the poor and ill. With Kenya and Tanzania as case studies, RAND Europe is exploring the extent to which unexploited potential synergies between industrial development and health systems can strengthen and contribute to faster and more inclusive growth.